Endogenous hormones and risk of breast cancer in postmenopausal women

Breast Disease

Volumn 24, Issue 1, 2005, Pages 3-15

  Hankinson, Susan E ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE SULFATE; PLACEBO; PRASTERONE; PROGESTERONE RECEPTOR; PROLACTIN; RALOXIFENE; SEX HORMONE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; TAMOXIFEN;

AGE DISTRIBUTION; ANDROGEN BLOOD LEVEL; BLOOD SAMPLING; BREAST CANCER; BREAST CARCINOGENESIS; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; ESTROGEN BLOOD LEVEL; ESTROGEN METABOLISM; FAMILY HISTORY; FEMALE; HORMONE ACTION; HORMONE URINE LEVEL; HUMAN; MENARCHE; NONHUMAN; OBESITY; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE;

EID: 33747373622     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/bd-2006-24102     Document Type: Review

References (120)

1. S.E. Hankinson, G.A. Colditz and W.C. Willett, Towards an integrated model for breast cancer etiology: The lifelong interplay of genes, lifestyle, and hormones, Breast Cancer Res 6(5) (2004), 213-218.
2. P.A. van den Brandt et al., Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk, Am J Epidemiol 152(6) (2000), 514-527.
3. T.J. Key et al., Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women, J Natl Cancer Inst 95(16) (2003), 1218-1226.
4. B. Fisher et al., Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J Natl Cancer Inst 90(18) (1998), 1371-1388.
5. J. Cuzick et al., Overview of the main outcomes in breast-cancer prevention trials, Lancet 361(9354) (2003), 296-300.
6. F. Berrino et al., Serum sex hormone levels after menopause and subsequent breast cancer, J Natl Cancer Inst 88(5) (1996), 291-296.
7. P.G. Toniolo et al., A prospective study of endogenous estrogens and breast cancer in postmenopausal women, J Natl Cancer Inst 87(3) (1995), 190-197.
8. M. Dowsett and E. Folkerd, Deficits in plasma oestradiol measurement in studies and management of breast cancer, Breast Cancer Res 7(1) (2005), 1-4.
9. P. Toniolo and A. Lukanova, The challenge of measuring circulating estradiol at low concentrations, Breast Cancer Res 7(2) (2005), 45-47.
10. P. Toniolo et al., Reliability of measurements of total, protein-bound, and unbound estradiol in serum, Cancer Epidemiol Biomarkers Prev 3(1) (1994), 47-50.
11. S.E. Hankinson et al., Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period, Cancer Epidemiol Biomarkers Prev 4(6) (1995), 649-654.
12. A. Micheli et al., Repeated serum and urinary androgen measurements in premenopausal and postmenopausal women, J Clin Epidemiol 44(10) (1991), 1055-1061.
13. P. Muti et al., Reliability of serum hormones in premenopausal and postmenopausal women over a one-year period, Cancer Epidemiol Biomarkers Prev 5(11) (1996), 917-922.
14. P. Muti et al., Fasting glucose is a risk factor for breast cancer: A prospective study, Cancer Epidemiol Biomarkers Prev 11(11) (2002), 1361-1368.
15. S.A. Missmer et al., Reproductibility of Plasma Steroid Hormones, Prolactin, and Insulin-like Growth Factor Levels Among Premenopausal Women Over a 2-3 Year Period, Cancer Epidemiol Biomarkers Prev (2006), in press.
16. W.C. Willett, Nutritional Epidemiology, 2nd ed., 1998.
17. B. Rosner, D. Spiegelman and W.C. Willett, Correction of logistic regression relative risk estimates and confidence intervals for random within-person measurement error, Am J Epidemiol 136(11) (1992), 1400-1413.
18. R. Carroll, Measurement Error in Non-Linear Models, (1995), London: Chapman and Hall.
19. A.A. van Landeghem et al., Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue, Cancer Res 45(6) (1985), 2900-2906.
20. J.H. Thijssen et al., Estrogens in tissues: Uptake from the peripheral circulation or local production, Steroids 50(1-3) (1987), 297-306.
21. S.R. Cummings et al., Serum estradiol level and risk of breast cancer during treatment with raloxifene, Jama 287(2) (2002), 216-220.
22. M.S. Beattie et al., Endogenous Sex Hormones, Risk of Breast Cancer, and Response to Tamoxifen: An Ancillary Study in the NSABP Breast Cancer Prevention Trial (P-1), JNCI (2006).
23. Y. Wu et al., Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors, Cancer Res 63(15) (2003), 4384-4388.
24. K.D. Roberts et al., Plasma estrone sulfate levels in postmenopausal women, Steroids 35(2) (1980), 179-187.
25. J.R. Pasqualini et al., Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients, J Clin Endocrinol Metab 81(4) (1996), 1460-1464.
26. T. Key et al., Endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of mine prospective studies, J Natl Cancer Inst 94(8) (2002), 606-616.
27. J.F. Dorgan et al., Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk, Cancer Epidemiol Biomarkers Prev 5(7) (1996), 533-539.
28. H.V. Thomas et al., A prospective study of endogenous; serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey, Br J Cancer 76(3) (1997), 401-405.
29. S.E. Hankinson et al., Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women, J Natl Cancer Inst 90(17) (1998), 1292-1299.
30. E. Barrett-Connor, N.J. Friedlander and K.T. Khaw, Dehydroepiandrosterone sulfate and breast cancer risk, Cancer Res 50(20) (1990), 6571-6574.
31. M. Kabuto et al., A prospective study of estradiol and breast cancer in Japanese women, Cancer Epidemiol Biomarkers Prev 9(6) (2000), 575-579.
32. J.A. Cauley et al., Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group, Ann Intern Med 130(4 Pt 1) (1999), 270-277.
33. K.J. Helzlsouer et al., A prospective study of endogenous hormones and breast cancer, Cancer Detect Prev 18(2) (1994), 79-85.
34. J. Manjer et al., Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden), Cancer Causes Control 14(7) (2003), 599-607.
35. R. Kaaks et al., Postmenopausal serum androgens, oestrogens and breast cancer risk: The European prospective investigation into cancer and nutrition, Endocr Relat Cancer 12(4) (2005), 1071-1082.
36. T.J. Key et al., A prospective study of urinary oestrogen excretion and breast cancer risk, Br J Cancer 73(12) (1996), 1615-1619.
37. N.C. Onland-Moret et al., Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer, Br J Cancer 88(9) (2003), 1394-1399.
38. A. Zeleniuch-Jacquotte et al., Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: Long-term results of a prospective study, Br J Cancer 90(1) (2004), 153-159.
39. S.A. Missmer et al., Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women, J Natl Cancer Inst 96(24) (2004), 1856-1865.
40. S. Martino et al., Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene, J Natl Cancer Inst 96(23) (2004), 1751-1761.
41. G.A. Colditz et al., Risk factors for breast cancer according to estrogen and progesterone receptor status, J Natl Cancer Inst 96(3) (2004), 218-228.
42. M.D. Althuis et al., Etiology of hormone receptor-defined breast cancer: a systematic review of the literature, Cancer Epidemiol Biomarkers Prev 13(10) (2004), 1558-1568.
43. R.B. Dickson and G.M. Stancel, Estrogen receptor-mediated processes in normal and cancer cells, J Natl Cancer Inst Monogr (27) (2000), 135-145.
44. R.G. Lapidus, S.J. Nass and N.E. Davidson, The loss of estrogen and progesterone receptor gene expression in human breast cancer, J Mammary Gland Biol Neoplasia 3(1) (1998), 85-94.
45. J.P. Costantino et al., Validation studies for models projecting the risk of invasive and total breast cancer incidence, J Natl Cancer Inst 91(18) (1999), 1541-1548.
46. H. Eliassen, Endogenous Steroid Hormone Concentraions and Risk of Breast Cancer: Does the Association Vary by a Women's Predicted Breast Cancer Risk? Journal of Clinical Oncology 24(12) (2006), 1823-1830.
47. G.A. Colditz and B. Rosner, Cumulative risk of breast cancer to age 70 years according to risk factor status: Data from the Nurses' Health Study, Am J Epidemiol 152(10) (2000), 950-964.
48. S.S. Tworoger et al., Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones, J Natl Cancer Inst 97(8) (2005), 595-602.
49. J. Tyrer, S.W. Duffy and J. Cuzick, A breast cancer prediction model incorporating familial and personal risk factors, Stat Med 23(7) (2004), 1111-1130.
50. A.N. Freedman et al., Cancer risk prediction models: A workshop on development, evaluation, and application, J Natl Cancer Inst 97(10) (2005), 715-723.
51. M.H. Gail et al., Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer, J Natl Cancer Inst 91(21) (1999), 1829-1846.
52. J.D. Yager and J.G. Liehr, Molecular mechanisms of estrogen carcinogenesis, Annu Rev Pharmacol Toxicol 36 (1996), 203-232.
53. J.G. Liehr, Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 21(1) (2000), 40-54.
54. W. Yue et al., Genotoxic metabolites of estradiol in breast: Potential mechanism of estradiol induced carcinogenesis, J Steroid Biochem Mol Biol 86(3-5) (2003), 477-486.
55. G.C. Kabat et al., Urinary estrogen metabolites and breast cancer: A case-control study, Cancer Epidemiol Biomarkers Prev 6(7) (1997), 505-509.
56. J. Schneider et al., Abnormal oxidative metabolism of estradiol in women with breast cancer, Proc Natl Acad Sci USA 79(9) (1982), 3047-3051.
57. W. Zheng et al., Correspondence re: G.C. Kabat et al., Urinary estrogen metabolites and breast cancer: A case-control study, Cancer Epidemiol, Biomark Prev 6 (1997), 505-509,
58. Cancer Epidemiol Biomarkers Prev 7(1) (1998), 85-86.
59. H. Adlercreutz et al., Diet and urinary estrogen profile in premenopausal omnivorous and vegetarian women and in premenopausal women with breast cancer, J Steroid Biochem 34(1-6) (1989), 527-530.
60. G.C. Kabat et al., Estrogen metabolism and breast cancer, Epidemiology 17(1) (2006), 80-88.
61. E.N. Meilahn et al., Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up, Br J Cancer 78(9) (1998), 1250-1255.
62. P. Muti et al., Estrogen metabolism and risk of breast cancer: A prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women, Epidemiology 11(6) (2000), 635-640.
63. J.A. Cauley et al., Estrogen metabolites and the risk of breast cancer in older women, Epidemiology 14(6) (2003), 740-744.
64. A. Wellejus et al., Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: A prospective study, Cancer Epidemiol Biomarkers Prev 14(9) (2005), 2137-2142.
65. R. Grattarola, Androgens in breast cancer. I. Atypical endometrial hyperplasia and breast cancer in married premenopausal women, Am J Obstet Gynecol 116(3) (1973), 423-428.
66. D.J. Liao and R.B. Dickson, Roles of androgens in the development, growth, and carcinogenesis of the mammary gland, J Steroid Biochem Mol Biol 80(2) (2002), 175-189.
67. L. Bernstein and R.K. Ross, Endogenous hormones and breast cancer risk, Epidemiol Rev 15(1) (1993), 48-65.
68. P. Ebeling and V.A. Koivisto, Physiological importance of dehydroepiandrosterone, Lancet 343(8911) (1994), 1479-1481.
69. K. Seymour-Munn and J. Adams, Estrogenic effects of 5-androstene-3 beta, 17 beta-diol at physiological concentrations and its possible implication in the etiology of breast cancer, Endocrinology 112(2) (1983), 486-491.
70. J.F. Dorgan et al., Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women, Cancer Epidemiol Biomarkers Prev 6(3) (1997), 177-181.
71. C. Lanari and A.A. Molinolo, Progesterone receptors-animal models and cell signalling in breast cancer. Diverse activation pathways for the progesterone receptor: Possible implications for breast biology and cancer, Breast Cancer Res 4(6) (2002), 240-243.
72. C. Campagnoli et al., Progestins and progesterone in hormone replacement therapy and the risk of breast cancer, J Steroid Biochem Mol Biol 96(2) (2005), 95-108.
73. W.Y. Chen et al., Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma, Cancer 101(7) (2004), 1490-1500.
74. V. Beral, Breast cancer and hormone-replacement therapy in the Million Women Study, Lancet 362(9382) (2003), 419-427.
75. J.E. Rossouw et al., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial, Jama 288(3) (2002), 321-333.
76. M.E. Freeman et al., Prolactin: Structure, function, and regulation of secretion, Physiol Rev 80(4) (2000), 1523-1631.
77. C.V. Clevenger et al., The role of prolactin in mammary carcinoma, Endocr Rev 24(1) (2003), 1-27.
78. C.V. Clevenger et al., Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop, Am J Pathol 146(3) (1995), 695-705.
79. K. Fields, E. Kulig and R.V. Lloyd, Detection of prolactin messenger RNA in mammary and other normal and neoplastic tissues by polymerase chain reaction, Lab Invest 68(3) (1993), 354-360.
80. C. Reynolds et al., Expression of prolactin and its receptor in human breast carcinoma, Endocrinology 138(12) (1997), 5555-5560.
81. E. Ginsburg and B.K. Vonderhaar, Prolactin synthesis and secretion by human breast cancer cells, Cancer Res 55(12) (1995), 2591-2595.
82. R.K. Partridge and R. Hahnel, Prolactin receptors in human breast carcinoma, Cancer 43(2) (1979), 643-646.
83. K. Liby et al., Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth, Breast Cancer Res Treat 79(2) (2003), 241-252.
84. J.H. Gutzman, K.K. Miller and L.A. Schuler, Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells, J Steroid Biochem Mol Biol 88(1) (2004), 69-77.
85. M.D. Schroeder, J. Symowicz and L.A. Schuler, PRL modulates cell cycle regulators in mammary tumor epithelial cells, Mol Endocrinol 16(1) (2002), 45-57.
86. C.M. Perks et al., Prolactin acts as a potent survival factor for human breast cancer cell lines, Br J Cancer 91(2) (2004), 305-311.
87. M.V. Maus, S.C. Reilly and C.V. Clevenger, Prolactin as a chemoattractant for human breast carcinoma, Endocrinology 140(11) (1999), 5447-5450.
88. I. Struman et al., Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: An efficient mechanism for the regulation of angiogenesis, Proc Natl Acad Sci USA 96(4) (1999), 1246-1251.
89. V. Herman et al., Serum prolactin after chest wall surgery: Elevated levels after mastectomy, J Clin Endocrinol Metab 52(1) (1981), 148-151.
90. D.Y. Wang et al., Relationship of blood prolactin levels and the risk of subsequent breast cancer, Int J Epidemiol 21(2) (1992), 214-221.
91. S.E. Hankinson et al., Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women, J Natl Cancer Inst 91(7) (1999), 629-634.
92. S.S. Tworoger et al., Plasma prolactin concentrations and risk of postmenopausal breast cancer, Cancer Res 64(18) (2004), 6814-6819.
93. J. Zapf and E.R. Froesch, Insulin-like growth factors/somatomedins: structure, secretion, biological actions and physiological role, Horm Res 24(2-3) (1986), 121-130.
94. M. Pollak et al., Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients, J Natl Cancer Inst 82(21) (1990), 1693-1697.
95. W. Ruan, C.B. Newman and D.L. Kleinberg, Intact and amino-terminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development, Proc Natl Acad Sci USA 89(22) (1992), 10872-10876.
96. M.N. Pollak, E.S. Schernhammer and S.E. Hankinson, Insulin-like growth factors and neoplasia, Nat Rev Cancer 4(7) (2004), 505-518.
97. J. Tornell et al., High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice, J Steroid Biochem Mol Biol 43(1-3) (1992), 237-242.
98. S.T. Ng et al., Growth hormone treatment induces mammary gland hyperplasia in aging primates, Nat Med 3(10) (1997), 1141-1144.
99. M. Ahlgren et al., Growth patterns and the risk of breast cancer in women, N Engl J Med 351(16) (2004), 1619-1626.
100. C.M. Friedenreich, Review of anthropometric factors and breast cancer risk, Eur J Cancer Prev 10(1) (2001), 15-32.
101. C. Lassarre et al., Serum insulin-like growth factors and insulin-like growth factor binding proteins in the human fetus. Relationships with growth in normal subjects and in subjects with intrauterine growth retardation, Pediatr Res 29(3) (1991), 219-225.
102. A. Juul et al., Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: Relation to age, sex, stage of puberty, testicular size, and body mass index, J Clin Endocrinol Metab 78(3) (1994), 744-752.
103. A.G. Renehan et al., Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis, Lancet 363(9418) (2004), 1346-1353.
104. R. Shi et al., IGF-I and breast cancer: A meta-analysis, Int J Cancer 111(3) (2004), 418-423.
105. S.E. Hankinson et al., Circulating concentrations of insulin-like growth factor-I and risk of breast cancer, Lancet 351(9113) (1998), 1393-1396.
106. P. Toniolo et al., Serum insulin-like growth factor-I and breast cancer, Int J Cancer 88(5) (2000), 828-832.
107. R. Kaaks et al., Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden, Cancer Causes Control 13(4) (2002), 307-316.
108. R.A. Krajcik et al., Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer, Cancer Epidemiol Biomarkers Prev 11(12) (2002), 1566-1573.
109. L. Keinan-Boker et al., Circulating levels of insulin-like growth factor I, its binding proteins -1,-2,-3, C-peptide and risk of postmenopausal breast cancer, Int J Cancer 106(1) (2003), 90-95.
110. D.E. Rollison et al., Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer, Int J Cancer 118(5) (2006), 1279-1284.
111. A.E. Allen et al., A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk, Br J Cancer 92(7) (2005), 1283-1287.
112. E.S. Schernhammer et al., Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk, Cancer Epidemiol Biomarkers Prev 14(3) (2005), 699-704.
113. H. Gronbaek et al., Serum insulin-like growth factors, insulin-like growth factor binding proteins, and breast cancer risk in postmenopausal women, Cancer Epidemiol Biomarkers Prev 13(11 Pt 1) (2004), 1759-1764.
114. W. Ruan et al., Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid, Endocrinology 136(3) (1995), 1296-1302.
115. R. Kaaks and A. Lukanova, Energy balance and cancer: The role of insulin and insulin-like growth factor-I, Proc Nutr Soc 60(1) (2001), 91-106.
116. R. Kaaks, Nutrition, hormones, and breast cancer: Is insulin the missing link? Cancer Causes Control 7(6) (1996), 605-625.
117. R.C. Travis et al., Melatonin and breast cancer: A prospective study, J Natl Cancer Inst 96(6) (2004), 475-482.
118. E.J. Sanchez-Barcelo et al., Melatonin-estrogen interactions in breast cancer, J Pineal Res 38(4) (2005), 217-222.
119. E.S. Schernhammer and S.E. Hankinson, Urinary melatonin levels and breast cancer risk, J Natl Cancer Inst 97(14) (2005), 1084-1087.
120. R.G. Stevens, Circadian disruption and breast cancer: From melatonin to clock genes, Epidemiology 16(2) (2005), 254-258.